logo-loader
viewAnteris Technologies Ltd

Anteris Technologies outlines new data showing DurAVR™ valve capabilities

The company presented the data at the TAVR Key Opinion Leader Symposium held on July 20.

Anteris Technologies Ltd - Anteris Technologies outlines new data showing DurAVR™ valve capabilities
Data shows the valve lasts longer and works better compared to other valves

Anteris Technologies Ltd (ASX:AVR) released new data at the TAVR Key Opinion Leader Symposium on July 20, 2020, which demonstrates the superiority of the DurAVR™ valve over existing valves.

The data was presented for the first time last week and suggests that when compared to other valves, DurAVR™ demonstrates the normal hemodynamic function of a healthy pre diseased valve.

“Better patient outcomes”

Chief Executive Officer Wayne Paterson said: “The data based on bench tests further replicates data seen in both animal and ongoing human studies and promises better patient outcomes in the future.

“Bringing the mean gradient down to within normal range (> 40 mm Hg to 4 mm Hg) will significantly improve patient quality of life as the DurAVR™ valve lasts longer and works better.”

The data showed the benefits of the valve

Valve replacement solution

The ADAPT® tissue platform, a next-generation technology with zero DNA and zero glutaraldehyde, is the only bioscaffold to demonstrate zero calcification after 10 years of use in complex cardiac surgery.

Its best-in-class ADAPT® tissue combined with its valve design has the potential to solve the problems associated with current aortic valve replacement options which are durability and preventing valve degradation.

Recordings of the symposium and the research note by Credit Suisse can be viewed at the following websites:

Quick facts: Anteris Technologies Ltd

Price: 3.03 AUD

ASX:AVR
Market: ASX
Market Cap: $17.91 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Anteris Technologies Ltd named herein, including the promotion by the Company of Anteris Technologies Ltd in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Anteris Technologies 'delivering on its goals despite pandemic'

Anteris Technologies Ltd's (ASX:AVR) Wayne Paterson tells Proactive's Andrew Scott the recent name change from Admedus is to reflect the single focus they have on structural heart and leveraging its assets into much more higher-value propositions. Paterson updates on its main trials which are...

1 month ago

2 min read